Lv4
760 积分 2021-04-26 加入
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
30天前
已完结
Primary central nervous system lymphoma: Evolving treatment strategies to achieve improved long-term disease control
1个月前
已完结
Covalent and Non-Covalent BTK Inhibition in Chronic Lymphocytic Leukemia Treatment
3个月前
已完结
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
4个月前
已完结
Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion
4个月前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
4个月前
已完结
中国高危人群乙型肝炎病毒再激活防治指南(2026年版)
4个月前
已完结
New BTK Inhibitors May Combat Resistance in CLL
5个月前
已完结
Anlotinib in progressive RAI-refractory differentiated thyroid cancer: long-term results and PET/CT prognostic markers
5个月前
已完结
Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia
5个月前
已完结
皖公网安备34019202002308
